會議議程

Executive Summary：
黃立楷醫師現為臺北醫學大學醫學院神經學科助理教授，亦是臺北醫學大學 雙和醫院神經內科主治醫師，長期投入臨床照護、教學與研究工作。他畢業於中國醫藥大學醫學系，完成神經科住院醫師與專科訓練後，持續深耕神經退化疾病與失智症領域。
在學術與研究方面，黃醫師專長涵蓋失智症照護、神經行為學、血管性認知障礙與中風後認知退化之影像與體液生物標記、以及意識障礙相關研究。他曾於多個國際與國內重要學術會議發表研究成果，包括阿茲海默症新藥臨床試驗、數位生物標記發展、血管性認知障礙研究、以及失智症治療與照護策略等，對臨床轉譯與公共衛生推動皆有重要貢獻。
在專業服務與社會參與方面，黃立楷醫師現任台灣失智症協會副秘書長，並自 2025 年起擔任社團法人新北市失智症協會理事長，積極推動失智政策倡議、照護網絡與跨領域合作。
Dr. Huang is an Assistant Professor in the Department of Neurology, School of Medicine, Taipei Medical University, and an Attending Physician at Taipei Medical University Shuang-Ho Hospital. He received his M.D. from China Medical University in Taiwan and completed his neurology residency and fellowship training at Shuang-Ho Hospital. Over the years, he has been deeply committed to clinical care, medical education, and research in neurology.
Dr. Huang’s research expertise spans dementia care, behavioral neuroscience, vascular cognitive impairment, neuroimaging and fluid biomarkers for post-stroke cognitive decline, and disorders of consciousness. He has presented widely at major national and international conferences, contributing to areas such as Alzheimer’s disease drug trials, digital biomarkers for cognition, and translational strategies for dementia diagnosis and treatment.
In addition to his academic achievements, Dr. Huang plays active leadership roles in professional and community services. He currently serves as Vice Secretary of the Taiwan Dementia Society and, since 2025, has been the Chairperson of the New Taipei City Dementia Association, where he promotes dementia policy advocacy, care networks, and interdisciplinary collaboration.

Lecture Abstract：
Alzheimer’s disease (AD) treatment is rapidly moving from symptomatic care toward genuine disease modification, driven by anti-amyloid monoclonal antibodies. Phase 3 trials show that lecanemab and donanemab slow decline in early AD by about 27% and up to 35–36%, respectively, with donanemab gaining FDA approval as Kisunla in 2024. However, the real-world impact remains debated due to modest benefit, high monitoring needs, and ARIA risk—particularly in APOE ε4 carriers. Kisunla’s 2025 label update introduced gradual titration to help reduce ARIA while maintaining efficacy.

New agents aim for better safety and efficiency. Trontinemab, using Brainshuttle™ technology, enhances brain delivery, enabling rapid amyloid reduction with lower ARIA rates. Treatment is also becoming more convenient: lecanemab’s weekly subcutaneous autoinjector (Leqembi IQLIK) was approved in 2025, and remternetug is being developed as a self-injected option.

Meanwhile, plasma p-tau217 testing—FDA-cleared in 2025—is reshaping diagnosis by reducing reliance on amyloid PET and enabling scalable, earlier identification of eligible patients.

Executive Summary：
Dr. Chih-Hao Chen is a stroke neurologist and clinical assistant professor in the Department of Neurology at National Taiwan University Hospital and the College of Medicine, National Taiwan University, Taipei, Taiwan. He received his MD in 2009 from National Taiwan University and completed his neurology residency training at National Taiwan University Hospital in 2013. He subsequently earned his PhD in epidemiology and preventive medicine in 2020. From 2021 to 2023, he undertook postdoctoral research training at the University of Calgary, Canada, focusing on advanced neuroimaging analysis of cerebral small vessel disease under the mentorship of Professor Eric E. Smith.
Dr. Chen’s research focuses on acute ischemic stroke management and cerebral small vessel disease, with particular emphasis on hereditary small vessel disorders such as CADASIL. His work integrates clinical epidemiology, neuroimaging biomarkers, and multicenter registry data to optimize thrombolysis and endovascular thrombectomy strategies. He is a core investigator of the Taiwan Registry of Endovascular Thrombectomy for Acute Ischemic Stroke (TREAT-AIS) and a co-founder of the Taiwan Associated Genetic & Non-genetic Small Vessel Disease (TAG-SVD) cohort. His studies have been published in leading journals including Neurology, Stroke, Journal of Stroke, and European Journal of Neurology, and have contributed to a better understanding of hemorrhagic risk, imaging phenotypes, and genetic modifiers—particularly the NOTCH3 R544C variant—in East Asian populations. He is now the Deputy Secretary General of the Taiwan Stroke Society, and also a member of the Asian and Oceanian Association of Neurology (AOAN) Young Neurologist Academy.

Lecture Abstract：
Acute ischemic stroke is the most common neurological emergency, characterized by heterogeneous etiologies, dynamic clinical evolution, and a narrow therapeutic time window. While modern stroke care increasingly emphasizes individualized decision making, most patients can still be managed effectively through standardized, evidence-based pathways. Since 2019, the Taiwan Stroke Society has published multiple comprehensive clinical guidelines covering acute and secondary stroke care. However, their length and complexity may limit rapid application in daily practice, particularly in busy clinical settings and aging societies with a growing stroke burden.
To address this gap, we developed PRISM (Practical Recommendations in Acute Ischemic Stroke Management)—a concise, structured, and clinically oriented framework designed to translate guideline-level evidence into real-world decision-making. PRISM integrates Class I and IIa recommendations from existing national guidelines with key evidence from major international trials published up to 2025. The framework encompasses five core domains spanning the continuum of stroke care: intravenous thrombolysis, endovascular thrombectomy, antiplatelet therapy, oral anticoagulation, and vascular risk factor management, including blood pressure, lipid levels, and glucose control.
Rather than replacing individualized clinical judgment, PRISM serves as a practical scaffold that enables clinicians to rapidly identify critical decision points from hyperacute reperfusion to early secondary prevention. By emphasizing clarity, feasibility, and workflow integration, PRISM aims to bridge the gap between comprehensive guidelines and bedside practice. In this presentation, I will introduce the conceptual design of PRISM and illustrate how this framework can support consistent, high quality acute ischemic stroke care across diverse clinical environments.

Executive Summary：
Dr. Tai obtained his M.D. degree from National Taiwan University (NTU) in 2006. He finished the residency program in the Department of Neurology at National Taiwan University Hospital (NTUH) (2008-2012). He was an attending physician in the Department of Neurology, E-DA Hospital from 2013-2014. He started his fellowship in movement disorders in the Department of Neurology, Westmead Hospital and Sydney Medical School, University of Sydney, Australia under Dr. Victor Fung’s supervision in 2015. He is now an attending neurologist in E-DA Hospital and a clinical lecturer in the School of Chinese Medicine for Post Baccalaureate, I-Shou University.
Dr. Tai is a member of International Parkinson and Movement Disorder Society and Taiwan Movement Disorders Society. Dr. Tai has clinical and research interests in electrophysiological analysis of movement disorders and deep brain stimulation.

Lecture Abstract：
Parkinson's Disease is the second most common neurodegenerative disorder. Since the introduction of levodopa in the 1960s, various treatments have been developed. However, as the disease progresses, there remains a significant need for better management of both motor and non-motor symptoms. Motor fluctuations and non-motor symptoms are two key challenges in the management of Parkinson's Disease.

In this lecture, we will base on the Evidence-Based Taiwan Consensus Recommendations for the treatment of Parkinson's disease and incorporate the latest advancements in treatment, including stem cell therapy and emerging clinical trials.

Executive Summary：
Dr. Jiann-Horng Yeh became a board-certified neurologist in 1993 after completing his residency training program at National Taiwan University Hospital, Taipei, Taiwan. He served as the secretary-general of the Taiwan Neurological Society from 2001 to 2003. Currently, he is the Deputy Superintendent for Education and Research at Shin Kong Wu Ho-Su Memorial Hospital, as well as a Professor and Associate Dean at the College of Medicine, Fu Jen Catholic University. Additionally, he serves as the President of the Taiwan Neuroimmunology Medical Society.
Dr. Yeh's research has focused on myasthenia gravis following a brief fellowship at the Institute of Molecular Medicine, University of Oxford, U.K., in 2003. Together with his mentor, Professor Hou-Chang Chiu, he established the largest center for myasthenia gravis care, which integrates diagnosis, treatment, emotional management, and social rehabilitation.

Lecture Abstract：
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fluctuating muscle weakness and fatigue due to autoantibody-mediated impairment of neuromuscular transmission. Globally, MG prevalence ranges from 40–180 per million, and in Taiwan the number of cases increased from 4,476 in 2013 to 5,752 in 2019, with a notable rise in generalized MG (GMG). GMG patients incur substantially higher healthcare costs and resource utilization than non-MG individuals. To standardize MG management, the Taiwan Neuroimmunology Medical Society convened an expert panel of 37 MG specialists and one patient representative to develop evidence-based guidelines. Organized into 11 thematic subgroups, the panel systematically reviewed literature from 2015–2024 and applied a Modified Delphi process to establish 48 consensus statements. These recommendations address diagnosis (antibody testing, electrophysiological studies), treatment (thymectomy, corticosteroids, novel biologics), and management of distinct MG subtypes, including ocular, early- and late-onset, MuSK-positive, refractory MG, myasthenic crisis, and neonatal MG. The guidelines emphasize early diagnosis, comprehensive management of comorbidities, and long-term strategies such as patient education, support, and tailored exercise programs. Collectively, these statements aim to improve care quality, optimize outcomes, and guide future research and therapeutic development within Taiwan’s medical community.